Direct-acting antivirals have significantly improved treatment outcomes in chronic hepatitis C (CHC), but side effects, drug resistance and cost mean that better treatments are still needed. Lipid metabolism is closely linked with hepatitis C virus (HCV) replication, and endocannabinoids are major regulators of lipid homeostasis. The cannabinoid 1 (CB1) receptor mediates these effects in the liver. We have previously shown upregulation of CB1 receptors in the livers of patients with CHC, and in a HCV cell-culture model. Here, we investigated whether CB1 blockade inhibited HCV replication. The antiviral effect of a CB1 antagonist, N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251), was examined in HCV strain JFH1 cell-culture and subgenomic replicon models. The effects on the expression of genes involved in lipid metabolism were also measured. CB1 short hairpin RNA (shRNA) was used to confirm that the effects were specific for the cannabinoid receptor. Treatment with AM251 strongly inhibited HCV RNA (~70 %), viral protein (~80 %), the production of new virus particles (~70 %) and virus infectivity (~90 %). As expected, AM251 reduced the expression of pro-lipogenic genes (SREBP-1c, FASN, SCD1 and ACC1) and stimulated genes promoting lipid oxidation (CPT1 and PPARα). This effect was mediated by AMP-activated protein kinase (AMPK). Stable CB1 knockdown of cells infected with HCV showed reduced levels of HCV RNA compared with controls. Thus, reduced CB1 signalling inhibits HCV replication using either pharmacological inhibitors or CB1 shRNA. This may be due, at least in part, to reduced lipogenesis, mediated by AMPK activation. We suggest that CB1 antagonists may represent an entirely new class of drug with activity against HCV.
AizakiH., LeeK. J., SungV. M., IshikoH., LaiM. M.2004; Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology 324:450–461 [View Article][PubMed]
ChengF. K. F., TorresD. M., HarrisonS. A.2014; Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy?. J Viral Hepat 21:1–8 [View Article][PubMed]
ChristopoulouF. D., KiortsisD. N.2011; An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther 36:10–18 [View Article][PubMed]
ClunyN. L., VemuriV. K., ChambersA. P., LimebeerC. L., BedardH., WoodJ. T., LutzB., ZimmerA., ParkerL. A.other authors2010; A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 161:629–642 [View Article][PubMed]
EngeliS., BöhnkeJ., FeldpauschM., GorzelniakK., JankeJ., BátkaiS., PacherP., Harvey-WhiteJ., LuftF. C.other authors2005; Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54:2838–2843 [View Article][PubMed]
FriedM. W., ShiffmanM. L., ReddyK. R., SmithC., MarinosG., GonçalesF. L.Jr, HäussingerD., DiagoM., CarosiG.other authors2002; Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982 [View Article][PubMed]
HardieD. G., PanD. A.2002; Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans 30:1064–1070 [View Article][PubMed]
HollanderP. A., AmodA., LitwakL. E., ChaudhariU.ARPEGGIO Study Group2010; Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial. Diabetes Care 33:605–607 [View Article][PubMed]
JacobsonI. M., GordonS. C., KowdleyK. V., YoshidaE. M., Rodriguez-TorresM., SulkowskiM. S., ShiffmanM. L., LawitzE., EversonG.other authors2013; Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368:1867–1877 [View Article][PubMed]
KlumpersL. E., FridbergM., de KamM. L., LittleP. B., JensenN. O., KleinloogH. D., EllingC. E., van GervenJ. M. A.2013; Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. Br J Clin Pharmacol 76:846–857 [View Article][PubMed]
LindenbachB. D., MeulemanP., PlossA., VanwolleghemT., SyderA. J., McKeatingJ. A., LanfordR. E., FeinstoneS. M., MajorM. E.other authors2006; Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A 103:3805–3809 [View Article][PubMed]
MankouriJ., TedburyP. R., GrettonS., HughesM. E., GriffinS. D. C., DallasM. L., GreenK. A., HardieD. G., PeersC., HarrisM.2010; Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase. Proc Natl Acad Sci U S A 107:11549–11554 [View Article][PubMed]
MannsM. P., McHutchisonJ. G., GordonS. C., RustgiV. K., ShiffmanM., ReindollarR., GoodmanZ. D., KouryK., LingM.-H., AlbrechtJ. K.2001; Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965 [View Article][PubMed]
MoreiraF. A., GriebM., LutzB.2009; Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 23:133–144 [View Article][PubMed]
NakashimaK., TakeuchiK., ChiharaK., HottaH., SadaK.2011; Inhibition of hepatitis C virus replication through adenosine monophosphate-activated protein kinase-dependent and -independent pathways. Microbiol Immunol 55:774–782 [View Article][PubMed]
OlmsteadA. D., KnechtW., LazarovI., DixitS. B., JeanF.2012; Human subtilase SKI-1/S1P is a master regulator of the HCV lifecycle and a potential host cell target for developing indirect-acting antiviral agents. PLoS Pathog 8:e1002468 [View Article][PubMed]
Osei-HyiamanD., LiuJ., ZhouL., GodlewskiG., Harvey-WhiteJ., JeongW. I., BátkaiS., MarsicanoG., LutzB.other authors2008; Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 118:3160–3169 [View Article][PubMed]
PawlotskyJ.-M.2011; Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 53:1742–1751 [View Article][PubMed]
SerranoA., Del ArcoI., Javier PavónF., MacíasM., Perez-ValeroV., Rodríguez de FonsecaF.2008; The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology 54:226–234 [View Article][PubMed]
SerranoA., PavonF. J., SuarezJ., Romero-CuevasM., BaixerasE., GoyaP., FonsecaF. R.2012; Obesity and the endocannabinoid system: is there still a future for CB11 antagonists in obesity. Curr Obes Rep 1:216–228 [View Article]
Targett-AdamsP., McLauchlanJ.2005; Development and characterization of a transient-replication assay for the genotype 2a hepatitis C virus subgenomic replicon. J Gen Virol 86:3075–3080 [View Article][PubMed]
Van GaalL., Pi-SunyerX., DesprésJ.-P., McCarthyC., ScheenA.2008; Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31:Suppl 2S229–S240 [View Article][PubMed]
WakitaT., PietschmannT., KatoT., DateT., MiyamotoM., ZhaoZ., MurthyK., HabermannA., KräusslichH.-G.other authors2005; Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791–796 [View Article][PubMed]
WuH. M., YangY. M., KimS. G.2011; Rimonabant, a cannabinoid receptor type 1 inverse agonist, inhibits hepatocyte lipogenesis by activating liver kinase B1 and AMP-activated protein kinase axis downstream of Gα i/o inhibition. Mol Pharmacol 80:859–869 [View Article][PubMed]